Septerna, Inc. (SEPN)

Septerna, Inc. went public on October 25, 2024. A collaboration with Novo Nordisk around May 2025 provided financial strength, extending the company's cash runway potentially beyond 2030. In August 2025, Septerna announced the dosing of the first participants in a Phase 1 clinical trial for SEP-631, which officially began on June 30, 2025. As of October 22, 2025, SEPN had returned 40.3% over the past month.

Based on the available information, there is no indication of demand seasonality for Septerna, Inc.'s products and services. The company's financial performance is more closely tied to its drug discovery platform and pipeline programs, which are not typically subject to seasonal fluctuations.

Septerna, Inc. is a clinical-stage biotechnology company focused on discovering and developing oral small molecule products targeting G protein-coupled receptors (GPCRs). The company leverages its Native Complex Platform™ to identify and optimize small molecule candidates for various therapeutic areas, with a focus on endocrinology, immunology and inflammation, and metabolic diseases. Septerna's pipeline includes the PTH1R Program for hypoparathyroidism, SEP-631 for chronic spontaneous urticaria and other mast cell diseases (Phase 1 clinical study began on June 30, 2025), a TSHR Program for Graves' disease and thyroid eye disease, and Metabolic Disorders Programs for obesity and type 2 diabetes. The company also explores other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease.

Septerna, Inc. is headquartered in South San Francisco, California, a hub for the biotech and pharmaceutical industries. The company's mission focuses on addressing global medical needs.

Septerna's brand reputation has been positively influenced by its innovative approach to drug discovery and strategic partnerships. The collaboration with Novo Nordisk validated Septerna's Native Complex Platform™ technology and enhanced the company's credibility. The initiation of the Phase 1 clinical trial for SEP-631 further contributes to a positive reputation by demonstrating progress in translating scientific breakthroughs into tangible patient benefits. There is no information found suggesting any negative events that have affected Septerna, Inc.'s reputation in the past year.

Septerna, Inc. is backed by a top-tier life science venture capital syndicate, with major institutional support from players like RA Capital. Mr. Bassan, a Partner at Samsara BioCapital, has served on the Board of Directors of Septerna, Inc. since November 2021.